October 28 from 11:30 am – 12:15 pm CDT
Theater B | Supported By: Genentech
Program Description
The treatment landscape for lupus nephritis (LN) continues to evolve, offering clinicians additional tools to help improve outcomes for patients facing this challenging autoimmune disease. Recent advances of therapies are expanding possibilities for patients with active lupus nephritis.
In this interactive session, Dr. Alvin Wells will provide an in-depth overview of the current unmet needs in lupus nephritis. This presentation will further highlight the chronic inflammation driven by B cells, the risk of irreversible kidney damage, and how evolving clinical guidance—including recent updates from ACR, EULAR and KDIGO—can inform the use of advanced therapies earlier to help improve patient outcomes.
Learning Objectives
- Highlight the Unmet Needs of Lupus Nephritis Patients
- Understand the Driving Mechanisms of Kidney Damage in Lupus Nephritis
- Discuss the Evolving Treatment Landscape of Advanced Therapies
For healthcare professionals only. This program is developed and offered by Genentech.
This is not an official program of the American College of Rheumatology.
Speakers
Presenter: Alvin Wells, MD, PhD, FACR, FACP
American Medical Group
Director of Rheumatology
Destin, Florida